Article

Cardiovascular Drugs and Therapy

, Volume 14, Issue 1, pp 49-53

First online:

Benefit of Antihypertensive Treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) Trial

  • Jerzy GasowskiAffiliated withHypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven
  • , Willem H. BirkenhägerAffiliated withErasmus University Rotterdam
  • , Jan A. StaessenAffiliated withHypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven
  • , Peter W. de LeeuwAffiliated withDepartment of Internal Medicine, University Hospital Maastricht

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

In this review we attempt to determine the role of calcium channel blockers in preventing cardiovascular sequelae in patients with both hypertension and diabetes mellitus. The data have been collected from three sources: post-hoc analyses of subgroups of diabetic patients in placebo-controlled hypertension trials (SHEP, Syst-Eur, Syst-China); stepped-care blood pressure-oriented trials (HOT, UKPDS); and comparative trials focusing primarily on metabolic aspects and intermediate endpoints (ABCD, FACET).

On balance, the data seem to indicate that long-acting calcium channel blockers score remarkably well in preventing cardiovascular complications in diabetic hypertensive patients.

hypertension diabetes prospective antihypertensive trials trial endpoints dihydropiridine-type long-acting calcium channel blockers ACE inhibitors diuretics beta-blockers